- Research article
- Open Access
Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer
Breast Cancer Research volume 21, Article number: 89 (2019)
Understanding the molecular alterations associated with breast cancer (BC) progression may lead to more effective strategies for both prevention and management. The current model of BC progression suggests a linear, multistep process from normal epithelial to atypical ductal hyperplasia (ADH), to ductal carcinoma in situ (DCIS), and then invasive ductal carcinoma (IDC). Up to 20% ADH and 40% DCIS lesions progress to invasive BC if left untreated. Deciphering the molecular mechanisms during BC progression is therefore crucial to prevent over- or under-treatment. Our previous work demonstrated that miR-671-5p serves as a tumor suppressor by targeting Forkhead box protein M1 (FOXM1)-mediated epithelial-to-mesenchymal transition (EMT) in BC. Here, we aim to explore the role of miR-671-5p in the progression of BC oncogenic transformation and treatment.
The 21T series cell lines, which were originally derived from the same patient with metastatic BC, including normal epithelia (H16N2), ADH (21PT), primary DCIS (21NT), and cells derived from pleural effusion of lung metastasis (21MT), and human BC specimens were used. Microdissection, miRNA transfection, dual-luciferase, radio- and chemosensitivity, and host-cell reactivation (HCR) assays were performed.
Expression of miR-671-5p displays a gradual dynamic decrease from ADH, to DCIS, and to IDC. Interestingly, the decreased expression of miR-671-5p detected in ADH coexisted with advanced lesions, such as DCIS and/or IDC (cADH), but not in simple ADH (sADH). Ectopic transfection of miR-671-5p significantly inhibited cell proliferation in 21NT (DCIS) and 21MT (IDC), but not in H16N2 (normal) and 21PT (ADH) cell lines. At the same time, the effect exhibited in time- and dose-dependent manner. Interestingly, miR-671-5p significantly suppressed invasion in 21PT, 21NT, and 21MT cell lines. Furthermore, miR-671-5p suppressed FOXM1-mediated EMT in all 21T cell lines. In addition, miR-671-5p sensitizes these cell lines to UV and chemotherapeutic exposure by reducing the DNA repair capability.
miR-671-5p displays a dynamic decrease expression during the oncogenic transition of BC by suppressing FOXM1-mediated EMT and DNA repair. Therefore, miR-671-5p may serve as a novel biomarker for early BC detection as well as a therapeutic target for BC management.
Breast cancer (BC) represents one of the most significant disease burdens of any cancer worldwide. Tumor-free survival rate relies on early and accurate pathological diagnosis and appropriate treatment. Breast carcinogenesis assumes a gradual transition from normal breast epithelial cells to atypical ductal hyperplasia (ADH), to ductal carcinoma in situ (DCIS), and eventually to invasive ductal carcinoma (IDC) . ADH is a proliferation of dysplastic, monotonous epithelial cell populations that include clonal subpopulations . DCIS is an intraductal neoplastic proliferation of epithelial cells that is separated from the breast stroma by an intact layer of the basement membrane and myoepithelial cells . Up to 20% ADH and 40% of DCIS lesions progress to invasive disease if untreated [2, 3]. Percutaneous core needle biopsy (CNB) following pathological analysis is the standard technique following an abnormal mammogram for diagnosis. However, CNB is less reliable in differentiating simple ADH (sADH) from ADH coexisted with DCIS and/or IDC (cADH), leading to misdiagnosis or unnecessary surgical excision. In addition, the management for patients with ADH and DCIS remains controversial. Most patients with sADH may only need a follow-up, whereas those cADH may undergo a conserving surgery followed by radiochemotherapy to reduce the risk of recurrence. However, radiochemoresistance is one of the major barriers to improving the free relapse and/or survival rate of patients [4,5,6,7]. Understanding the molecular mechanism during the stepwise progression of breast tumorigenesis is essential for identifying reliable biomarkers to prevent over- or under-treatment of patients diagnosed with ADH or DCIS.
Epithelial-to-mesenchymal transition (EMT) is a vital process to promote BC progression and chemoresistance . The hallmark of EMT is the loss of E-cadherin expression and apical–basal cell polarity, accompanied by the gain of mesenchymal characteristics, including the acquisition of cell migration and invasion abilities, as well as an increased expression of mesenchymal markers, such as vimentin, fibronectin, and N-cadherin . Up to 90% of human tumors originate from differentiated epithelium and are susceptible to EMT [10, 11]. Forkhead box protein M1 (FOXM1) is a transcription factor required for a wide spectrum of essential biological functions, including cell proliferation, cell cycle progression, cell renewal, cell differentiation, and tissue homeostasis. FOXM1 is an essential inducer of EMT to promote tumor progression and metastasis. In addition, FOXM1 contributes to drug resistance in breast cancer cells by enhancing DNA-damage repair pathways [12,13,14,15,16]. In our previous studies, we demonstrated that miR-671-5p inhibits proliferation and invasion by targeting FOXM1-mediated EMT and DNA repair in BC. In our present work, we extend our study to further demonstrate that miR-671-5p undergoes a dynamic change during the oncogenesis from ADH to DCIS to IDC in formalin-fixed paraffin-embedded (FFPE) tissue, blood, and a T21 series cell model that mimics specific stages of human BC progression. In addition, we demonstrated the role of miR-671-5p in inhibiting FOXM1-mediated EMT and DNA repair in every stage of the BC oncogenic transformation, as well as in cells under UV and chemotherapeutic agent treatment.
Materials and methods
Cell lines and cell culture
The 21T series cell lines were obtained as a kind gift from Dr. Vimla Band (University of Nebraska Medical Center). They were originally derived from the same patient with metastatic BC, including H16N2 (derived from normal epithelia), 21PT (derived from ADH), 21NT (derived from primary DCIS), and 21MT (derived from pleural effusion of lung metastasis). . The cell lines were cultured in α-MEM supplemented with 10% fetal bovine serum, 2 mM l-glutamine (ThermoFisher Sci, USA), insulin (1 mg/ml), epidermal growth factor (12.5 ng/ml), hydrocortisone (2.8 mM), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, and 50 mg/mL gentamycin reagent (Sigma Chemical, USA) in a 37 °C humidified incubator with 5% CO2.
Tissue blocks were retrieved from the Department of Pathology at the George Washington University Hospital and Beijing Cancer Hospital at the Peking University School of Oncology. The blocks were subject to microdissection into the following components: normal, hyperplasia, DCIS, and IDC, as previously described . The breast lesions were confirmed by pathological diagnosis following CNB and surgical excision. The blood samples were collected from 4 patients with benign breast lesions, 2 with ADHs, 6 with DCISs, and 1 with confirmed IDC diagnosis from the George Washington University Hospital with the IRB approval, and the informed consents were obtained from the participants.
Microdissection, RNA extraction, and quantitative real-time reverse transcription-PCR (qRT-PCR)
Total RNA from FFPE samples and cell lines were isolated and quantitated as described previously . Plasma was obtained as the cell-free supernatant remaining after centrifuging blood, collected in the presence of an anticoagulant. Total RNA was prepared and purified from a 300-μl plasma using miRNeasy Serum/Plasma Kit (Qiagen). miR-671-5p (Acc#: MIMAT00038800) expression was assayed using the Taqman MiRNA Reverse Transcription Kit (Applied Biosystems), and target gene expression (SYBR Green) was analyzed using the ABI 7300 System, as described previously .
Dual luciferase reporter assay
Cells were plated (2 × 105 cells/well) in 24-well plates and co-transfected with 100 ng of DNA with pEZX-FOXM1-3′UTR (wild type or mutant) expression clones inserted downstream of a secreted Gaussia luciferase (GLuc) reporter and 100 ng of DNA with pEZX-miR-671-5p or the pEZX-MT scrambled control (mock), using the FuGENE Transfection Reagent (Promega). Luciferase activities were determined with Secrete-PairTM Dual Luminescence Assay Kit (Genecopoeia). GLuc luciferase activities were normalized to SEAP luciferase expression for each sample.
miRNA and plasmid transfection
miRNA transient-transfection was performed as described [19, 20]. Briefly, miRNA precursors (miR-671-5p mimic, inhibitors, and mock controls) were transiently transfected into each of the 21T series cell lines by Lipofectamine RNAiMAX (Life Technologies) using the Opti-MEM I Reduced Serum Medium (Life Technologies). Cells were subjected to further analysis after 24 h, 48 h, and 72 h post-transfection. For rescue experiments, the pcDNA3.1/FOXM1 plasmid containing full-length human FOXM1 cDNA without 3′UTR was a kind gift of Dr. Suyun Huang (MD Anderson Cancer Center). The T21 cell lines were co-transfected with miR-671-5p and pcDNA3.1-FOXM1 or pcDNA3.1 empty vector.
Protein extraction and Western blotting
Cell lysates were prepared using the RIPA Buffer (ThermoFisher Sci) according to the manufacturer’s protocol, and Western blot analysis with chemiluminescent detection was performed using the ProteinSimple imaging system as described . The following antibodies and dilution factors were used: FOXM1 rabbit polyclonal antibody (13147-1-AP, 1:800, Proteintech), anti-rabbit vimentin (5741, 1:200 Cell Signaling), anti-rabbit E-cadherin (3195, 1:400, Cell Signaling), anti-rabbit beta-actin (4970 s, 1:2000, Cell Signaling), anti-rabbit IgG conjugated to horseradish peroxidase (7074S, 1:2000, Cell Signaling), and anti-mouse IgG (7076S, 1:2,000, Cell Signaling).
Immunofluorescence assays were performed as described earlier [21, 22]. Briefly, 2 × 105 cells were plated on glass coverslips in 6-well plates and allowed to settle overnight. Cells were fixed in 2% paraformaldehyde and then stained with primary and secondary antibodies. Confocal images were obtained using an LSM 510 Confocal Microscope (Carl Zeiss). The number of nuclei containing at least one localized area of immunofluorescence was determined by examination of the confocal images. Antibodies for immunofluorescence assays used were as follows: anti-rabbit vimentin (5741, 1:200 Cell Signaling), anti-rabbit E-cadherin (3195, 1:200, Cell Signaling), anti-BRCA1 (ab16780, 1:500, Abcam), Alexa Flour 568 goat anti-mouse IgG (1:500, Invitrogen), and Alexa Flour 568 goat anti-mouse IgG (1:500, Invitrogen).
Matrigel invasion assays
Matrigel invasion assays were performed using the BD BioCoat™ Matrigel™ Invasion Chamber (BD Biosciences) as previously described . Briefly, prior to the start of each experiment, 500 μl of warm (37 °C) serum-free DMEM medium was added to the upper and lower chambers and allowed to rehydrate for 2 h in a 37 °C cell culture incubator, while 8 × 104 cells were transfected by either miR-671-5p mimic or mock control for 24 h and seeded onto the top chamber of pre-wetted inserts. Cells were incubated in a Matrigel chamber in a 37 °C humidified incubator with 5% CO2 for 24 h. The invasive cells present were fixed, stained with the Diff-Quick staining solution and counted (five microscope fields under the × 10 lens). Experiments were conducted twice and in duplicates for each cell line. Cell counts were performed on five non-overlapping random fields for each chamber, and four chambers were counted for each experimental point, with the percentage of invasive cells being normalized to corresponding controls.
Radio-chemosensitivity and MTT assays
The cells transfected with miR-671-5p mimic, inhibitor, or their corresponding mock controls were washed with 1× PBS. The MTT (100 μl) working solution (5 mg/ml stock MTT diluted in opti-MEM to 0.5 mg/ml working solution) was added to each well and incubated at 37 °C with 5% CO2 for 3 h. The MTT solution was then removed, and 100 μl DMSO was added to each well and incubated in a 37 °C humidified incubator with 5% CO2 for 30 min. Color development was measured using a spectrophotometer at 570 nm on a plate reader (BIO-TEK Instruments) and quantified as per the manufacturer’s protocol (Promega, USA). For the radiosensitivity assay, the cells transfected with miR-671-5p mimic or inhibitor and their mock controls were plated on coverslips. The medium was replaced with PBS, and cells were irradiated at 20 J/m2 (the dose was measured using a UVX radiometer [UVP Inc., Upland, CA]) using a 254-nm UV-C lamp (UVP Inc., Upland, CA) through 3-mm-pore-size isopore/micropore polycarbonate filters (catalog number TSTP02500; Millipore), as described . After irradiation, the previously removed medium was added back. MTT was added and absorbance was measured. For the chemosensitivity assay, the cells transfected with miR-671-5p mimic, inhibitor, or their corresponding mock controls were seeded in 96-well tissue culture plates. Cells were treated with various concentrations of cisplatin (20 μM), 5-fluorouracil (5-Fu, 5 μM), paclitaxel (10 μM), or epirubicin (100 nM). MTT was added, and absorbance was measured at different time points.
Plasmid treatment and host cell reactivation (HCR) assays
pCMVLuc reporter gene plasmids (a kind gift from Dr. Kenneth H. Kraemer, National Cancer Institute, NIH) were dissolved in 10 mm Tris-HCl, 1 mm EDTA, pH 8 (TE buffer) to a final concentration of 100 μg/ml and poured in a petri dish to form 1D 2-mm thick layer. For UV treatment, the petri dish was placed on ice and irradiated by 1000 J/m2 of UV light. For the chemotherapeutic agents treatment, 1 μl aliquots of a stock solution of cisplatin (0, 5, 10, 20 μM), 5-Fu (0, 5, 25, 125 μM), epirubicin (200 nM), and paclitaxel (0, 50, 100, 200 μM) (Sigma-Aldrich, St. Louis, MO) in TE were added to 10 μg plasmid DNA dissolved in 200 μl TE buffer, and the samples were incubated at 37 °C for 6 h. At the end of the incubation period, 1 m NaCl was added to a final concentration of 0.2 m NaCl, and plasmid DNA was precipitated with 2 volumes of ethanol, extensively washed with 70% ethanol and dissolved in TE buffer. DNA repair capability was assessed using a host cell reactivation (HCR) assay with the pCMVLuc reporter gene plasmid treated by UV or chemotherapeutic agents . Briefly, 4 μl (200 ng) of CsCl-purified pCMVLuc plasmids, damaged or undamaged, were co-transfected with miR-671-5p mimic, inhibitor, or their corresponding mock controls into 21T series cells using FuGENE® HD Transfection Reagent (Promega). For the rescue experiment, the pCMVLuc plasmids were co-transfected with miRNAs plus pcDNA3.1-FOXM1 plasmid. The luciferase activity was measured.
miR-671-5p expression in clinical samples was analyzed by the exact two-sided binomial test. Data were expressed as mean ± standard error (S.E.). Permutation tests were performed for MTT assays between control and miR-671-5p mimic-transfected groups. The Student t test (two-tailed) was applied to Matrigel assay between the control and the miR-671-5p-transfected group. P values less than 0.05 were considered statistically significant.
Expression of miR-671-5p decreased gradually in breast lesions during the BC oncogenic transformation
In our previous work, we found decreased expression of miR-671-5p in BC compared to their adjacent normal tissues. We reasoned that miR-671-5p expression play an important role in BC oncogenic transformation. We firstly analyzed miR-671-5p expression in clinical samples undergoing the transition steps from ADH, DCIS to IDC in 7 FFPE BC tissues by isolating normal, ADH, DCIS to IDC components using microdissection technique. miR-671-5p expression was decreased gradually in ADH, DCIS, and IDC compared to normal tissues (Fig. 1a) in all seven cases. These results suggest that decreased expression of miR-671-5p is an early and gradual event during the progression of human BC.
Circulating miRNAs can be used as biomarkers for disease diagnosis, prognosis, and treatment. To determine whether the dynamic change of miR-671-5p can be readily detected in blood, we analyzed miR-671-5p expression by qRT-PCR in serum from patients of a separate cohort including 3 benign breast lesions, 1 fibrocystic breast, 3 ADHs, 6 DCISs, and 1 IDC. Consistent with the results from FFPE samples, miR-671-5p expression decreased gradually from benign breast lesions or fibrocystic breast to ADH, DCIS, and IDC (Fig. 1b). These results suggest that decreased miR-671-5p is an important risk factor in BC development and may serve as a biomarker detectable in both FFPE and serum.
Decreased expression of miR-671-5p in cADH but not in sADH
Based on the clinical needs for the development of diagnostic markers to distinguish sADH and cADH, we next asked whether the miR-671-5p expression can distinguish between the two types of ADH. To address this, we examined the expression of miR-671-5p from a separate cohort. We found significantly decreased miR-671-5p expression in 25 of 32 (78%) cADHs compared with their matched adjacent normal controls (p < 0.01). In contrast to the cADHs group, the decreased miR-671-5p expression was only observed in 12 of 28 (42.85%) in sADHs. There is no statistically significant difference between sADH compared with their matched adjacent normal controls (Fig. 1c). However, there is a statistically significant difference between cADH and sADH groups (p < 0.001). This data suggests that aberrantly expressed miR-671-5p might be used to distinguish ADHs from ADHs.
miR-671-5p directly targets FOXM1 in all 21T cell lines
We observed different effects of miR-671-5p on FOXM1 between triple-negative BC (TNBC) cell lines and non-triple negative ones . We then attempted to determine whether miR-671-5p exerts its effect differently during BC oncogenesis. We employed the 21T cell lines, which were originally derived from the same patient with metastatic BC (Band reference?). These cell lines have been served to mimic specific distinct stages of human BC progression. The cell lines allowed us to monitor the dynamic changes of miR-671-5p through different stages during the oncogenic transition . We found a significant inverse correlation between miR-671-5p and FOXM1 expression in the 21T cell lines (Fig. 2a). Forced expression of miR-671-5p significantly repressed FOXM1 expression in both mRNA and protein levels (Fig. 2b and Fig. 5c). Transfection of miR-671-5p inhibitor resulted in significantly increased FOXM1 expression. The repression of miR-671-5p is more significant in 21 NT and 21MT, suggesting that it affects FOXM1 expression in each step of BC progression, especially in DCIS and IDC stages. To confirm that miR-671-5p directly targets FOXM1 in BC progression, the luciferase reporter assay was performed. After co-transfection of the plasmids containing miR-671-5p and FOXM1 3′UTR wild-type sequence into the 21T cells, luciferase activity was significantly decreased in all four cell lines compared to the co-transfection of those containing either miR-671-5p plus FOXM1 3′UTR mutant sequence or scrambled control plus FOXM1 3′UTR wild-type sequence (Fig. 2c, d). Our data demonstrate that miR-671-5p specifically targets the 3′UTR of FOXM1 at 828–848 nt in all 21T cell lines, suggesting that miR-671-5p targets FOXM1 in all stages during BC transition.
miR-671-5p inhibits FOXM1-mediated proliferation and invasion during the BC oncogenic transition
We have previously demonstrated the tumor suppressor function of miR-671-5p in BC cell lines . In this study, we focused on the role of miR-671-5p expression during breast oncogenesis. We firstly addressed the effect of miR-671-5p on cell proliferation. After ectopic expression of miR-671-5p, cell proliferation was significantly inhibited in 21NT and 21MT cell lines in a dose- and time-dependent manner, as compared to mock control. However, miR-671-5p overexpression did not show significant proliferative inhibition in H16N2 and 21PT cell lines (Fig. 3a, top panel). Conversely, transfection of miR-671-5p inhibitor significantly increased cell proliferation in 21MT cell lines, slightly in 21NT, but not in H16N2 and 21PT (Fig. 3a, middle panel). These results indicate an anti-proliferative effect of miR-671-5p, which is more significant in the advanced progression of BC. We then performed rescue experiments to further validate that FOXM1 targeting is involved in miR-671-5P-mediated proliferation inhibition in BC cells. Forced expression of FOXM1 not only abrogated the suppressive proliferation induced by miR-671-5p transfection in 21NT and 21MT cell lines, but also increased proliferation in 21PT and H16N2 cell lines (Fig. 3a, bottom panel).
We next tested the effect of miR-671-5p on cell invasion during the progression of BC using Transwell assays. miR-671-5p ectopic expression resulted in a significant inhibition of invasive capability in 21PT (46%), 21NT (30%), and 21MT (59%), but not in H16N2 cells when compared to the mock control. Conversely, transfection of miR-671-5p inhibitor significantly elevated cell invasion in 21MT cells, moderately in 21PT and 21NT (albeit not statistically significant) but not in H16N2 (Fig. 4a) when compared to the inhibitor mock. Rescue experiments by re-expression of FOXM1 not only abrogated the invasion suppression induced by miR-671-5p in 21TP, 21NT, and 21MT, but also increased cell invasion in H16N2 cells (Fig. 4b). These results suggest that miR-671-5p might suppress invasion by targeting FOXM1 in both precancerous lesions and invasive stages.
miR-671-5p reverses the FOXM1-induced EMT in the 21T cell lines during the BC progression
In previously published work, we demonstrated that miR-671-5p reversed EMT to mesenchymal-to-epithelial transition (MET) phenotype in MDA-MB-231 BC cell lines by targeting FOXM1 . We now aimed to determine whether miR-671-5p affects EMT during BC progression. The morphological change is an important parameter in EMT, widely used for assessing EMT. After 48 h and 96 h from the time of transfection, the morphology of cells was evaluated by microscopy. Significant morphological changes (from elongated, fibroblast-like spindle-shaped to round-shaped cells) were observed in miR-671-5p-transfected 21T series cells compared to the mock-transfected controls. Such observations indicate that the forced expression of miR-671-5p leads to the acquisition of MET phenotype in all 21T cells. Transfection of miR-671-5p inhibitor or re-expression of FOXM1 reversed the 21T cell lines from MET to EMTstage (Fig. 5a and Additional file 1: Figure S1). Consistent with the morphological changes, immunofluorescence and Western blot analyses revealed an upregulation of the epithelial marker E-cadherin as well as concomitant downregulation of the EMT marker, vimentin in miR-671-5p-transfected cells when compared to the mock control. Reversed expression of E-cadherin and vimentin was observed with the transfection of miR-671-5p inhibitor compared to that of the inhibitor mock. At the same time, FOXM1 was significantly downregulated in all miR-671-5p-transfected 21T cell lines compared to the mock controls (Fig. 5b, c). Rescue experiments by transfections of FOXM1 abrogated the effect of miR-671-5p on EMT alleviation. These findings suggest that miR-671-5p prevents oncogenesis by inhibiting FOXM1-mediated EMT.
miR-671-5p sensitizes the 21T series cell lines to UVC exposure and chemotherapeutic agents
Radiation therapy or chemotherapy is usually given after a lumpectomy when a patient was diagnosed with DCIS or IDC . However, radiochemoresistance is a common barrier for survival rate improvement [6, 7, 9, 25]. Having demonstrated that miR-671-5p inhibits EMT, which is implicated in the development of BC therapeutic resistance , we next addressed whether miR-671-5p reverses therapeutic resistance by inhibiting FOXM1-mediated EMT and/or DNA repair function. To observe the dynamic effects of miR-671-5p on radiotherapy during the BC progression, we treated miR-671-5p-transfected 21T cells with UV exposure or chemotherapeutic agents in indicated doses after 24 h and 48 h following miR-transfection. The sensitivity was determined by the MTT assay. As shown in Fig. 6a, miR-671-5p overexpression either significantly or partially increased cell sensitivity to UV and cisplatin, paclitaxel, and epirubicin, but not to 5-Fu in 21T cell lines compared to mock-transfected cells. Inhibition of miR-671-5p resulted in an inverse effect. Additionally, we performed rescue experiments to further validate whether FOXM1 was involved in miR-671-5p-mediated sensitization of T21 cells to UVC exposure and chemotherapeutic agents. Re-expression of FOXM1 with pcDNA3.1/FOXM1 plasmid in 21T cell lines reduced cell sensitivity to UV and chemotherapeutic agents in all 21T cells (Additional file 2: Figure S2A). These data suggest that miR-671-5p may be a new therapeutic target for DCIS and IDC as it reverses radiochemoresistance through inhibition of FOXM1.
miR-671-5p reduced DNA repair capability in 21T cell lines
Alteration in DNA repair efficiency has been considered one of the critical factors involved in radiochemoresistance . Consistent with an important role of FOXM1 in DNA repair , our prior work demonstrated that miR-671-5p decreased DNA repair capability by targeting FOXM1, leading to increased sensitivity to radiotherapy and chemotherapy in MDA-MB-231 cells . To further determine the dynamic effects of miR-671-5p on radiochemoresistance during the progression of BC, we quantitatively assessed DNA damage and repair capability of miR-671-5p to UV and chemotherapeutic agents by HCR assays. pCMU-Luc vector pre-treated by UVC and chemotherapeutic agents was co-transfected with miR-671-5p into 21T cells and the luciferase activity was measured. Cells co-transfected with UV pre-damaged pCMU-Luc and miR-671-5p exhibited significantly reduced post-UV HCR activity compared to the mock-co-transfected one in 21MT cell lines. The slightly reduced post-UV HCR activity was still observed in H16N2, 21PT, and 21NT, despite the difference did not reach statistical significance. In contrast, co-transfection of pre-damaged pCMU-Luc with miR-671-5p inhibitor inversed the post-UV HCR activity in all 21T cells compared to the inhibitor mock one (Fig. 6b). The post-chemo HCR was examined by co-transfection of pCMU-Luc pre-damaged by chemotherapeutic agents with miR-671-5p. Co-transfection of cisplatin pre-damaged pCMU-Luc with miR-671-5p exhibited significantly reduced post-cis HCR activity compared to the mock-co-transfected control in H16N2, 21NT, and 21MT. Surprisingly, significantly increased post-cis HCR activity was observed in 21PT cells, suggesting ADH might be a specific stage in which other factors may play a role in miR-671-5p-mediated FOXM1 inhibition. Co-transfection of cisplatin pre-damaged pCMU-Luc with miR-671-5p inhibitor rescued the luciferase activity in all 21T cell lines. Interestingly, although miR-671-5p did not affect 5-Fu sensitivity in 21T cells (Fig. 6a), we still observed suppression of miR-671-5p on post-5Fu HCR in H16N2, 21TPT, and 21NT cell lines (Fig. 6b), suggesting that miR-671-5p-mediated FOXM1 inhibition does not affect 5-Fu resistance. For post-paclitaxel and epirubicin HCR, we found significantly or partially reduced DNA repair capability when co-transfection of paclitaxel or epirubicin pre-damaged pCMU-Luc with miR-671-5p in 21PT, 21NT, and 21MT, which is also consistent with the effect of miR-671-5p in paclitaxel or epirubicin drug resistance. Rescue experiment was performed by co-transfection of pre-damaged pCMU-Luc with miR-671-5p or mock plus pcDNA3.1-FOXM1 or pcDNA3.1 empty plasmid. These data showed that re-expression of FOXM1 abrogated the alleviating effect of miR-671-5p on DNA repair compared to the pcDNA3.1 empty plasmid one (Fig. 7b). Taken together, we demonstrated that at least partially, miR-671-5p plays an important role in reducing DNA damage by targeting FOXM1, which improves the sensitivity to chemo-radiation therapy for patients with both earlier and later stage BC.
miR-671-5p suppressed the expression of FOXM1 downstream genes involving in EMT and DNA repair pathways
Having demonstrated that miR-671-5p represses EMT and DNA repair by targeting FOXM1 during BC progression, we asked if the inhibition of miR-671-5p on FOXM1 expression affects the downstream gene(s) involved in EMT and DNA repair during BC progression. EMT program is mediated by complex signaling networks induced by different factors. We analyzed the expression of these genes when miR-671-5p was overexpressed. As expected, overexpression of miR-671-5p resulted in significant downregulation of TGF-β and VEGF in 21NT and 21MT (Additional file 1: Figure S1). FOXM1 has been reported as a transforming growth factor-beta (TGF-β) inducer and enhanced TGF-β-induced EMT [28, 29]. In addition, FOXM1 is a transcriptional factor of vascular endothelial growth factor (VEGF) during EMT [30,31,32]. These results suggest that miR-671-5p may serve as a key repressor of FOXM1-mediated EMT.
FOXM1 is an essential regulator of DNA damage response and genotoxic agent resistance . We hypothesized that miR-671-5p sensitize 21T cells to radio-chemo treatment by targeting FOXM1 and modulating FOXM1 downstream genes involved in DNA repair. Overexpression of miR-671-5p significantly reduced the expression of two downstream genes of FOXM1, BRIP1 (BRCA1 interacting protein C-terminal helicase 1), a DNA repair protein that works with BRCA1 to repair damaged DNA , and RAD51 (RAD51 Recombinase), a protein which assists in the repair of DNA double-strand breaks  (Additional file 3: Figure S3). These results suggest that miR-671-5p sensitizes radiochemotherapy by targeting FOXM1-mediated DNA repair proteins, BRIP1 and RAD51.
The current model of human BC progression proposes a linear multistep process which initiates as ADH, evolves into DCIS, and culminates in the potentially lethal stage of IDC that requires a dynamic accumulation of molecular alterations. Prompt detection and intervention of early BC and/or precancerous lesions improves the patients’ survival rate. Our data showed a gradual, dynamic decreased expression of miR-671-5p and its tumor suppressor function during the oncogenesis of human BC in the 21T series cell lines that mimics specific stages of human BC progression. In clinical samples, the expression of miR-671-5p displays a gradually dynamic decrease from ADH, to DCIS, to IDC in both FFPE tissues and serums. Statistically significant correlation was seen between the histological grade and miR-671-5p down-expression in FFPE tissues. To determine whether the dynamic change of miR-671-5p can be used as a circulating biomarker, we also analyzed miR-671-5p expression in serum from individuals diagnosed with benign breast lesion, ADH, DCIS, and IDC. Consistent with the results from FFPE tissues, we observed a gradually decreased miR-671-5p expression from benign breast lesions, to ADHs, DCISs, and IDC (Fig. 1b). Although the gradually decreased miR-671-5p expression was not statistically significant among the different steps due to their small numbers, it provides a clue for the application of circulating miR-671-5p expression in BC diagnosis. More importantly, we found that the expression levels of miR-671-5p can differentiate between cADH and sADH. The functional analysis revealed that miR-671-5p inhibits proliferation in advanced stages and invasion in early stages in 21T cell lines. The observation in which miR-671-5p is able to enhance cell proliferation more significantly in advanced stages may be explained by the presence of high endogenous miR-671-5p levels in H16N2 and 21PT cell lines, which reduces the efficiency of forced ectopic miR-671-5p by transfection. Our results suggest that decreased miR-671-5p is an important risk factor in BC progression and may serve as a biomarker in both FFPE tissue and serum for early detection.
The mechanism underlying decreased miR-671-5p during BC progression is not yet fully understood. miRNA expression is associated with complex multilevel regulations such as somatic copy-number alterations (SCNAs), transcriptional and post-transcriptional mechanisms, and the effects of endogenous (hormones, cytokines) and exogenous (xenobiotics) compounds in relation to cell types, physiological states of the body, and various external factors . Further investigation is needed to explore genomic and epigenetic alterations in miR-671-5p regulation.
FOXM1 is associated with EMT phenotype  and DNA damage repair . miR-671-5p appears to suppress EMT and sensitize to UV and chemotherapeutic (except 5-Fu) in 21NT and 21MT cell lines more significantly than in 21PT and H16N2 cell lines via the suppression of FOXM1. To the best of our knowledge, this is the first study to show a linear tumor-suppressive role of miR-671-5p in BC progression, which might serve as a biomarker for early detection and prognosis (Fig. 7).
In this study, we found that miR-671-5p significantly reversed the resistance to UV, cisplatin, and paclitaxel treatment (albeit slightly to epirubicin) and that such findings are consistent with the predicted function of miR-671-5p in DNA repair modulation (Fig. 6). Although FOXM1 has been associated with 5-Fu resistance, we did not observe any effect of miR-671-5p on resistance to 5-Fu in 21T cell lines. Nevertheless, we still observed a slightly reduced DNA repair capability to 5-Fu damaged DNA after miR-671-5p transfection (Fig. 6). This may be due to the fact that in addition to the DNA repair pathway, the resistance to 5-Fu is conferred by additional mechanisms. For example, increased thymidylate synthase and dihydropyrimidine dehydrogenase (DPD) are major molecular mechanism responsible for 5-FU resistance .
We expanded our previous work to assess the tumor suppressor function of miR-671-5p during the oncogenesis of BC. Loss of miR-671-5p leads to the activation of FOXM1-mediated EMT progression and enhanced DNA repair capability, resulting in a gradually aggressive molecular event in the development of radio/chemoresistance (Fig. 7). The present study raises the possibility that miR-671-5p may be a potential biomarker for BC early detection and therapy.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Atypical ductal hyperplasia
Ductal carcinoma in situ
Forkhead box protein M1
Host cell reactivation
Invasive ductal carcinoma
Triple-negative breast cancer
Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(10):5974–9.
Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med. 2015;372(1):78–89.
Cowell CF, Weigelt B, Sakr RA, Ng CK, Hicks J, King TA, Reis-Filho JS. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol. 2013;7(5):859–69.
Masson S, Bahl A. The management of ductal carcinoma in situ: current controversies and future directions. Clin Oncol (R Coll Radiol). 2013;25(5):275–82.
Early Breast Cancer Trialists' Collaborative G, Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162–77.
EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group BN, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381–7.
Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, et al. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. Brit J Cancer. 2014;111(1):46–54.
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Bio. 2019;20(2):69–84.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.
Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013;19(11):1438–49.
Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.
Zona S, Bella L, Burton MJ, Nestal de Moraes G, Lam EW. FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. Biochim Biophys Acta. 2014;1839(11):1316–22.
Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A, Li Y, Azmi AS, Miele L, Sarkar FH. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem. 2011;112(9):2296–306.
Xue YJ, Xiao RH, Long DZ, Zou XF, Wang XN, Zhang GX, Yuan YH, Wu GQ, Yang J, Wu YT, et al. Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med. 2012;10:200. https://doi.org/10.1186/1479-5876-10-200.
Raychaudhuri P, Park HJ. FoxM1: a master regulator of tumor metastasis. Cancer Res. 2011;71(13):4329–33.
Saba R, Alsayed A, Zacny JP, Dudek AZ. The role of Forkhead box protein M1 in breast cancer progression and resistance to therapy. Int J Breast Cancer. 2016;2016:9768183.
Band V, Zajchowski D, Swisshelm K, Trask D, Kulesa V, Cohen C, Connolly J, Sager R. Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res. 1990;50(22):7351–7.
Chen L, Li Y, Fu Y, Peng J, Mo MH, Stamatakos M, Teal CB, Brem RF, Stojadinovic A, Grinkemeyer M, et al. Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One. 2013;8(1):e54213.
Tan X, Fu Y, Chen L, Lee W, Lai Y, Rezaei K, Tabbara S, Latham P, Teal CB, Man Y et al: miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer. Oncotarget. 2016;7(1):293–307.
Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, Teal CB, Man YG, Brem RF, Fu SW. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res. 2014;16(5):435.
Tan X, Anzick SL, Khan SG, Ueda T, Stone G, Digiovanna JJ, Tamura D, Wattendorf D, Busch D, Brewer CC, et al. Chimeric negative regulation of p14ARF and TBX1 by a t (9;22) translocation associated with melanoma, deafness, and DNA repair deficiency. Hum Mutat. 2013;34(9):1250–9.
Tan XH, Wu XL, Ren SY, Wang HY, Li ZW, Alshenawy W, Li WM, Cui JT, Luo GB, Siegel RS, et al. A point mutation in DNA polymerase beta (POLB) gene is associated with increased progesterone receptor (PR) expression and intraperitoneal metastasis in gastric cancer. J Cancer. 2016;7(11):1472–80.
Fu Y, Lian Y, Kim KS, Zhang L, Hindle AK, Brody F, Siegel RS, McCaffrey TA, Fu SW: BP1 homeoprotein enhances metastatic potential in ER-negative breast cancer. J Cancer. 2010;24;1:54–62.
Polo SE, Roche D, Almouzni G. New histone incorporation marks sites of UV repair in human cells. Cell. 2006;127(3):481–93.
Balanis N, Wendt MK, Schiemann BJ, Wang Z, Schiemann WP, Carlin CR. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem. 2013;288(25):17954–67.
Singh M, Yelle N, Venugopal C, Singh SK. EMT: mechanisms and therapeutic implications. Pharmacol Ther. 2018;182:80–94.
Lynam-Lennon N, Reynolds JV, Pidgeon GP, Lysaght J, Marignol L, Maher SG. Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma. Radiat Res. 2010;174(6):703–11.
Kong FFZY, Yuan HH, Wang JY, Zhao M, Gong XD, Liu F, Zhang WY, Wang CR, Jiang B. FOXM1 regulated by ERK pathway mediates TGF-β1-induced EMT in NSCLC. Oncol Res. 2014;22(1):29–37.
Massagué J. TGFbeta in Cancer. Cell. 2008;134(2):215–30.
Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, Huang S. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res. 2008;68(21):8733–42.
Karadedou CT, Gomes AR, Chen J, Petkovic M, Ho KK, Zwolinska AK, Feltes A, Wong SY, Chan KYK, Cheung YN, et al. FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene. 2012;31(14):1845–58.
Sistigu A, Di Modugno F, Manic G, Nistico P. Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. Cytokine Growth Factor Rev. 2017;36:67–77.
Monteiro LJ, Khongkow P, Kongsema M, Morris JR, Man C, Weekes D, Koo CY, Gomes AR, Pinto PH, Varghese V, et al. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene. 2013;32(39):4634–45.
Im J, Lawrence J, Seelig D, Nho RS. FoxM1-dependent RAD51 and BRCA2 signaling protects idiopathic pulmonary fibrosis fibroblasts from radiation-induced cell death. Cell Death Dis. 2018;9(6):584.
Gulyaeva LFKN. Regulatory mechanisms of microRNA expression. J Transl Med. 2016;14(1):143.
Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochimica Et Biophysica Acta-Reviews on Cancer. 2007;1775(1):92–102.
Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13(8):1551–69.
We would like to thank Dr. Kenneth H. Kraemer at NCI/NIH for providing us with the pCMVLuc reporter gene plasmid, Dr. Vimla Band at University of Nebraska for providing us with the 21T series cell lines, and Dr. Suyun Huang at MD Anderson Cancer Center for providing us with pcDNA3.1/FOXM1 plasmid containing full-length human FOXM1 cDNA.
This research was supported by the Earlier.org - Friends for an Earlier Breast Cancer Test® (to XT), the Gray Foundation Grant (to SWF), the Dr. Liqun Huang Breast Cancer Biomarker Fund (to SWF), and the Elaine H. Snyder Cancer Research Award (to SWF).
Ethics approval and consent to participate
The use of all achieved FFPE tissue blocks from the George Washington University Hospital and Beijing Cancer Hospital was approved by the respective IRB committees.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure S1. Transfection of miR-671-5p inhibitor abrogated the effect of miR-671-5p on cell morphology. (PNG 144 kb)
Figure S2. Transfection of FOXM1 abrogated the effect of miR-671-5p on radiochemotherapy and DNA repair capability. (PNG 162 kb)
Figure S3. miR-671-5p suppressed the expression of FOXM1 downstream genes involving EMT and DNA repair pathway. (PNG 139 kb)